EP
MYGN icon

Essential Partners’s Myriad Genetics MYGN Stock Holding History

Essential Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5K Buy
3,934
+1,348
+52% +$6.12K 0.01% 856
2026
Q1 		$11.6K Sell
2,586
-4,291
-62% -$22.4K ﹤0.01% 1178
2025
Q4 		$42.3K Buy
6,877
+1,728
+34% +$12.5K 0.01% 655
2025
Q3 		$37.2K Buy
5,149
+3,979
+340% +$23.6K 0.01% 686
2025
Q2 		$6.21K Buy
+1,170
New +$6.91K ﹤0.01% 992

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Essential Partners's MYGN Position: Q2 2026 in Review

Essential Partners increased its Myriad Genetics (MYGN) stake by 52% in Q2 2026, buying an estimated $6.12K and bringing the position to 3,934 shares worth $22.5K. The position accounts for 0.01% of the portfolio, ranked #856.

Essential Partners first reported a position in MYGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $42.3K in Q4 2025. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Essential Partners held 3,934 shares of Myriad Genetics worth $22.5K as of Q2 2026.
  • Essential Partners bought 1,348 Myriad Genetics shares in Q2 2026, an estimated $6.12K.
  • Myriad Genetics made up 0.01% of Essential Partners's portfolio in Q2 2026, its #856 holding.
  • Essential Partners first reported a position in Myriad Genetics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Myriad Genetics position peaked at $42.3K in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.